Key result
Amiodarone, a class III antiarrhythmic medication with numerous noncardiac adverse effects, may stimulate an unforeseen increase in prostate-specific antigen.
Why the study?
Does amiodarone cause an increase in prostate-specific antigen?
Does amiodarone cause an increase in prostate-specific antigen?
Amiodarone use may be associated with an unforeseen increase in prostate-specific antigen, adding to its known multisystem side effect profile.
Alerts clinicians to monitor PSA on amiodarone; leaves open causality and clinical relevance pending prospective data.
Amiodarone is a commonly used antiarrhythmic medication (AAM). While it is approved only for the treatment of life-threatening ventricular arrhythmias,1 it is more broadly used for the treatment of refractory atrial arrhythmias, particularly atrial fibrillation (AF). While effective, amiodarone usage carries with it a multitude of mild to potentially significant or even life-threatening side effects coupled with relatively long half-life, which require frequent multisystem monitoring. Amiodarone has numerous noncardiac adverse effects, including involvement of the lung, eye, skin, thyroid, peripheral nervous system, and liver.
No takes yet. Share an insight, caveat, or question.
Wiener et al. (2021) studied Arrhythmias. Amiodarone was evaluated. Amiodarone, a class III antiarrhythmic medication with numerous noncardiac adverse effects, may stimulate an unforeseen increase in prostate-specific antigen.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: